{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:18:52Z","timestamp":1784042332888,"version":"3.55.0"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hunan Medical Association of China","award":["HMA202001002"],"award-info":[{"award-number":["HMA202001002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled from the intensive care unit. Factors affecting the meropenem trough concentration were analyzed, and a multiple linear regression model was constructed. Logistic regression analyses were used to investigate the relationship between Ctrough and clinical efficacy. A total of 64 patients were enrolled, in whom 210 meropenem concentrations were measured. Of the total, 60.9% (39\/64) were considered clinically successful after treatment. Ctrough may increase with increased blood urea nitrogen, albumin, and concomitant antifungal use. By contrast, concentration may decrease with increased endogenous creatinine clearance rate. Six variables, including Ctrough\/minimum inhibitory concentration (MIC) &gt; 4, were associated with the efficacy of meropenem. There was an independent correlation between Ctrough\/MIC &gt; 4 and efficacy after fully adjusting for confounding factors. Based upon renal function indexes, it is possible to predict changes in meropenem concentration and adjust the dosage precisely and individually. Ctrough\/MIC &gt; 4 is a potential instrument to predict successful treatment with meropenem.<\/jats:p>","DOI":"10.3390\/antibiotics11050670","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T13:06:23Z","timestamp":1652706383000},"page":"670","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["C\/MIC &gt; 4: A Potential Instrument to Predict the Efficacy of Meropenem"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-4457","authenticated-orcid":false,"given":"Yichang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"School of Medicine, University of New South Wales, Sydney, NSW 2052, Australia"},{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Intensive Care Unit, The Second Xiangya Hospital, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Intensive Care Unit, The Second Xiangya Hospital, Central South University, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-8305","authenticated-orcid":false,"given":"Miao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China"},{"name":"International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mcna.2018.12.008","article-title":"Community-acquired Pneumonia and Hospital-acquired Pneumonia","volume":"103","author":"Lanks","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/653060","article-title":"Mortality, attributable mortality and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia","volume":"51","author":"Muscedere","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hraiech, S., Alingrin, J., Dizier, S., Brunet, J., Forel, J.M., La Scola, B., Roch, A., Papazian, L., and Pauly, V. (2013). Time to intubation is associated with outcome in patients with community-acquired pneumonia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074937"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amjmed.2004.06.028","article-title":"Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia","volume":"117","author":"Mortensen","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1183\/09031936.00093010","article-title":"Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia","volume":"37","author":"Rello","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","article-title":"Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria","volume":"10","author":"Hansen","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.09-1547","article-title":"Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality","volume":"137","author":"Restrepo","year":"2010","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jiph.2020.09.018","article-title":"Molecular insights of Carbapenem resistance Klebsiella pneumoniae isolates with focus on multidrug resistance from clinical samples","volume":"14","author":"Indrajith","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-018-0966-7","article-title":"Meropenem\/Vaborbactam: A Review in Complicated Urinary Tract Infections","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy","volume":"50","author":"Wiseman","year":"1995","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated with Piperacillin\/Tazobactam or Meropenem from the MERINO Study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40266-016-0431-9","article-title":"Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract","volume":"34","author":"Zhou","year":"2017","journal-title":"Drugs Aging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1128\/AAC.00531-16","article-title":"Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients","volume":"60","author":"Alobaid","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/jac\/dkq317","article-title":"Population pharmacokinetics of meropenem in burn patients","volume":"65","author":"Doh","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: A prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-019-0268-x","article-title":"Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia","volume":"19","author":"Marquet","year":"2019","journal-title":"Drugs R&D"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","article-title":"Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis","volume":"54","author":"Ehmann","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/AAC.04166-14","article-title":"Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units","volume":"59","author":"Jaruratanasirikul","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: Population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study","volume":"28","author":"Zhou","year":"2011","journal-title":"Drugs Aging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","article-title":"Dosing regimen of meropenem for adults with severe burns: A population pharmacokinetic study with Monte Carlo simulations","volume":"70","author":"Allen","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/jac\/dku564","article-title":"Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients","volume":"70","author":"Roberts","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","first-page":"276","article-title":"Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children","volume":"22","author":"Cies","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-016-2172-4","article-title":"Population pharmacokinetics of meropenem in elderly patients: Dosing simulations based on renal function","volume":"73","author":"Usman","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01083-12","article-title":"Case-control study of drug monitoring of \u03b2-lactams in obese critically ill patients","volume":"57","author":"Hites","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: Association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.38.5.931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","author":"Mouton","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: Proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: A randomised controlled trial","volume":"40","author":"Carrette","year":"2014","journal-title":"Intensive Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"ofab371","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Roger, C., and Louart, B. (2021). Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?. Microorganisms, 9.","DOI":"10.3390\/microorganisms9071505"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: A retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00228-022-03291-5","article-title":"Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance","volume":"78","author":"Razzazzadeh","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/IDR.S345385","article-title":"The Evaluation of Meropenem Dosing Regimens against ESBL-Producing Escherichia coli in ICU Patients Using Monte Carlo Simulation","volume":"15","author":"Win","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_40","first-page":"00025","article-title":"Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection","volume":"22","author":"Lan","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1469-0691.2006.01454.x","article-title":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing","volume":"12","author":"Kahlmeter","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00134-010-2105-0","article-title":"Optimization of meropenem dosage in the critically ill population based on renal function","volume":"37","author":"Crandon","year":"2011","journal-title":"Intensive Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0021321","DOI":"10.1128\/JCM.00213-21","article-title":"Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition","volume":"59","author":"Humphries","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bianco, G., Boattini, M., Comini, S., Iannaccone, M., Cavallo, R., and Costa, C. (2022). Rapid determination of ceftazidime\/avibactam susceptibility of carbapenemase-producing Enterobacterales directly from blood cultures: A comparative evaluation of EUCAST disc diffusion RAST and direct Etest\u00ae RAST. J. Antimicrob. Chemother., dkac092.","DOI":"10.1093\/jac\/dkac092"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.12901","article-title":"Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid","volume":"81","author":"Rizk","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.1866","article-title":"Pharmacokinetics of Imipenem\/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration","volume":"36","author":"Boucher","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","year":"2011","journal-title":"Crit. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ccc.2010.09.006","article-title":"Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock","volume":"27","author":"Varghese","year":"2011","journal-title":"Crit. Care Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/cid\/cix443","article-title":"Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient with Renal Failure","volume":"65","author":"Mahmoudi","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ccm.2018.07.004","article-title":"The Role of Biomarkers in the Diagnosis and Management of Pneumonia","volume":"39","author":"Sungurlu","year":"2018","journal-title":"Clin. Chest Med."},{"key":"ref_52","first-page":"4300","article-title":"Clinical significance of serum procalcitonin level monitoring on early diagnosis of severe pneumonia on children","volume":"19","author":"Zhu","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_53","first-page":"26","article-title":"Diagnostic efficacy of serum procalcitonin, C-reactive protein concentration and clinical pulmonary infection score in Ventilator-Associated Pneumonia","volume":"34","author":"Chen","year":"2018","journal-title":"Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4187\/respcare.02741","article-title":"C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia","volume":"59","author":"Porfyridis","year":"2014","journal-title":"Respir. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.repc.2017.05.009","article-title":"CKD-EPI versus Cockcroft-Gault formula for predicting contrast-induced nephropathy following percutaneous coronary intervention in patients without significant renal impairment","volume":"37","author":"Nunes","year":"2018","journal-title":"Rev. Port. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/FTD.0000000000000323","article-title":"A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients","volume":"38","author":"Mathew","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CCM.0000000000000771","article-title":"The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: A systematic review and metaanalysis","volume":"43","author":"Valachis","year":"2015","journal-title":"Crit. Care Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/jac\/dky370","article-title":"Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections","volume":"73","author":"Burger","year":"2018","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/670\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:24Z","timestamp":1760137884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["antibiotics11050670"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11050670","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}